Celldex Therapeutics Inc Asset Resilience Ratio
Celldex Therapeutics Inc asset resilience ratio. Celldex Therapeutics Inc (CLDX) has an Asset Resilience Ratio of 81.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Celldex Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Celldex Therapeutics Inc (2009–2025)
Asset resilience ratio of Celldex Therapeutics Inc from 2009 to 2025. This chart shows how Celldex Therapeutics Inc's Asset Resilience Ratio has changed over time. Read CLDX liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Celldex Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CLDX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $415.73 Million | 81.32% |
| Total Liquid Assets | $415.73 Million | 81.32% |
Asset Resilience Insights
- Very High Liquidity: Celldex Therapeutics Inc maintains exceptional liquid asset reserves at 81.32% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Celldex Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Celldex Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Celldex Therapeutics Inc Asset Resilience Ratio by Year (2009–2025)
Celldex Therapeutics Inc asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Celldex Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 84.00% | $489.70 Million | $582.98 Million | -3.96pp |
| 2024-12-31 | 87.96% | $696.92 Million | $792.34 Million | +4.87pp |
| 2023-12-31 | 83.09% | $386.88 Million | $465.63 Million | +4.98pp |
| 2022-12-31 | 78.11% | $275.52 Million | $352.74 Million | -4.90pp |
| 2021-12-31 | 83.01% | $369.11 Million | $444.65 Million | +19.16pp |
| 2020-12-31 | 63.85% | $150.59 Million | $235.84 Million | +20.78pp |
| 2019-12-31 | 43.07% | $52.95 Million | $122.93 Million | -1.67pp |
| 2018-12-31 | 44.74% | $69.71 Million | $155.81 Million | +13.33pp |
| 2017-12-31 | 31.41% | $99.14 Million | $315.62 Million | -7.02pp |
| 2016-12-31 | 38.43% | $147.31 Million | $383.36 Million | -26.08pp |
| 2015-12-31 | 64.51% | $217.78 Million | $337.58 Million | -5.25pp |
| 2014-12-31 | 69.76% | $173.02 Million | $248.01 Million | +31.28pp |
| 2013-12-31 | 38.49% | $133.58 Million | $347.10 Million | -8.56pp |
| 2012-12-31 | 47.05% | $59.06 Million | $125.54 Million | +4.79pp |
| 2011-12-31 | 42.26% | $41.41 Million | $97.99 Million | +6.05pp |
| 2010-12-31 | 36.21% | $39.81 Million | $109.94 Million | +18.08pp |
| 2009-12-31 | 18.13% | $25.45 Million | $140.36 Million | -- |
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzo… Read more